Navigation Links
Symmetry Medical to Report Second Quarter 2008 Financial Results on August 6, 2008
Date:7/29/2008
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 2Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 3Rib-X Pharmaceuticals Expands License Agreement with Yale University on New Ribosome Technology 2Undocumented Hispanics Face Health Care Roadblocks in U S 60405 1Undocumented Hispanics Face Health Care Roadblocks in U S 60405 2Anesiva Announces Date for 2009 Annual Meeting of Stockholders to Vote on Proposed Merger 60400 1Anesiva Announces Date for 2009 Annual Meeting of Stockholders to Vote on Proposed Merger 60400 2Anesiva Announces Date for 2009 Annual Meeting of Stockholders to Vote on Proposed Merger 60400 3BMP Sunstone Announces November Investor Conference Participation 14664 1BMP Sunstone Announces November Investor Conference Participation 14664 2